Sanara MedTech Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
SMTI$32.10+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net Revenue | $86,672,425 | $64,989,842 |
| Cost of goods sold | 8,139,901 | 7,852,686 |
| Gross profit | 78,532,524 | 57,137,156 |
| Operating expenses | ||
| Selling, general and administrative | 76,559,863 | 56,994,753 |
| Research and development | 5,703,362 | 4,132,425 |
| Depreciation and amortization | 4,923,224 | 3,675,026 |
| Change in fair value of earnout liabilities | (1,938,451) | (3,449,895) |
| Total operating expenses | 85,247,998 | 61,352,309 |
| Operating loss | (6,715,474) | (4,215,153) |
| Other income (expense) | ||
| Interest expense | (3,128,395) | (475,783) |
| Share of losses from equity method investments | (90,007) | - |
| Interest income | 21,978 | - |
| Gain on disposal of investment | - | 251,034 |
| Total other income (expense) | (3,196,424) | (224,749) |
| Net loss | (9,911,898) | (4,439,902) |
| Less: Net loss attributable to noncontrolling interest | (247,351) | (136,705) |
| Net loss attributable to Sanara MedTech shareholders | $(9,664,547) | $(4,303,197) |
| Net loss per share of common stock, basic and diluted | $(1.14) | $(0.52) |
| Weighted average number of common shares outstanding, basic and diluted | 8,484,224 | 8,278,949 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.